'Here, we investigate the susceptibility of natural variants of the main protease (Mpro/3CLpro) of SARS-CoV-2 to protease inhibitors. Multiple single amino acid changes in Mpro confer resistance to nirmatrelvir (the active component of Paxlovid).'

#SarsCov2 #COVID19 #Preprint #Protease #ProteaseInhibitors

https://www.biorxiv.org/content/10.1101/2022.08.07.503099v2